Diagnosing Drug Allergy: the T is the Key
Diagnosing Drug Allergy the T is the Key
University Hospital, Antwerp
300 participants
May 21, 2024
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to validate a newly developed test in the diagnosis of patients with amoxicillin allergy (i.e. T-cell activation test). The main questions the study aims to assess are the reliability and applicability of this test. Participants will be asked to visit the hospital 1, 3 or 5 times during which blood is collected and when applicable, allergy skin testing is performed.
Eligibility
Inclusion Criteria4
- Participants are eligible if they:
- Are ≥ 6 years
- Are capable of informed consent, or if appropriate, participants have an acceptable individual capable of giving consent on the participant's behalf (e.g. parent or guardian of a child under 18 years of age)
- Have a suspected history of amoxicillin allergy
Exclusion Criteria3
- Patients who are lacking capacity or do not have an acceptable individual capable to provide informed consent
- Pregnant women
- Breastfeeding women
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
A blood sample will be taken which is needed for the T-cell activation test (TAT). The TAT will than be performed by trained laboratory personnel.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06409884